Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.50 |
| ▸ | CHRNG | P07510 | 1/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.50 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | CHRND | Q07001 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythro-Hydrobupropion SCHEMBL3320146 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL1227545 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL1226880 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL30252298 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL1226819 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL1229064 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL3320155 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL3320024 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL30252231 | 1.00 | SLC6A4 (0.65) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 | |
| Erythro-Hydrobupropion SCHEMBL6429272 | 0.98 | SLC6A4 (0.63) | SLC6A4SLC6A2CYP2C19SLC6A3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986391-A1 | DRUG COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Isanas AG (CH) | 2022-04-27 | — | — | EP | claimed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | GENASE THERAPEUTICS B V (NL) | 2025-12-25 | — | — | US | disclosed |
| EP-4469461-B1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B V (NL) | 2025-10-15 | — | — | EP | disclosed |
| EP-4469461-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | Genase Therapeutics B.V. (NL) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144332-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B.V. (NL) | 2023-08-03 | — | — | WO | disclosed |
| CN-116211862-A | Bupropion hydrochloride/dextromethorphan sustained and controlled release liquid suspension and preparation method and application thereof | 五邑大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-115697314-A | Use of bupropion and dextromethorphan combinations for treating neurological disorders | 安泰赛普生物风投二代有限责任公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-114712357-A | Combination of dextromethorphan and bupropion for the treatment of depression | 安泰赛普生物风投二代有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114712356-A | Combination of dextromethorphan and bupropion for the treatment of depression | 安泰赛普生物风投二代有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114712358-A | Combination of dextromethorphan and bupropion for the treatment of depression | 安泰赛普生物风投二代有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3986391-A1 | DRUG COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Isanas AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-112437659-B | Combination of dextromethorphan and bupropion for the treatment of depression | 安泰赛普生物风投二代有限责任公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | CCNA1, KRAS, RSU1 | SLC6A4 2822/4885SLC6A2 1889/4885CYP2C19 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.